Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.56 |
| ▸ | GHSR | Q92847 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | EDNRB | P24530 | 1/20 | 0.52 |
| ▸ | EDNRA | P25101 | 1/20 | 0.52 |
| ▸ | TYMS | P04818 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12126221 | 0.85 | KMT2A (0.56) | MAPTKMT2AMEN1LMNAHPGD | |
| SCHEMBL16785737 | 0.84 | TSHR (0.67) | MAPTALDH1A1HTTPFKFB3TSHR | |
| SCHEMBL31110643 | 0.84 | TSHR (0.74) | MAPTALDH1A1HTTPFKFB3GHSR | |
| SCHEMBL812673 | 0.84 | TSHR (0.74) | MAPTALDH1A1HTTPFKFB3GHSR | |
| SCHEMBL3697796 | 0.83 | MEN1 (0.60) | MAPTALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL10092842 | 0.82 | NSD2 (0.56) | MAPTKMT2AMEN1EDNRALMNA | |
| SCHEMBL9616665 | 0.82 | ALDH1A1 (0.56) | MAPTALDH1A1HTTPFKFB3GHSR | |
| SCHEMBL9616624 | 0.82 | ALDH1A1 (0.56) | MAPTALDH1A1HTTPFKFB3GHSR | |
| SCHEMBL3259317 | 0.82 | ALDH1A1 (0.64) | MAPTALDH1A1HTTPFKFB3GHSR | |
| SCHEMBL9616551 | 0.81 | MAPT (0.54) | MAPTALDH1A1HTTPFKFB3GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0462179-A4 | NOVEL SULFONAMIDES AS RADIOSENSITIZERS | — | 1992-03-18 | — | — | EP | claimed |
| EP-0462179-A1 | NOVEL SULFONAMIDES AS RADIOSENSITIZERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-27 | — | — | EP | claimed |
| WO-1990009787-A1 | NOVEL SULFONAMIDES AS RADIOSENSITIZERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-09-07 | — | — | WO | claimed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| EP-0462179-A4 | NOVEL SULFONAMIDES AS RADIOSENSITIZERS | — | 1992-03-18 | — | — | EP | disclosed |
| EP-0462179-A1 | NOVEL SULFONAMIDES AS RADIOSENSITIZERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-27 | — | — | EP | disclosed |
| WO-1990009787-A1 | NOVEL SULFONAMIDES AS RADIOSENSITIZERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | MAPT 3923/4885ALDH1A1 4428/4885HTT 3321/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | MAPT 3923/4885ALDH1A1 4428/4885HTT 3321/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | MAPT 3923/4885ALDH1A1 4428/4885HTT 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.